Mouse Gesture Recognition for Human Computer Interaction

In the field of Computer Science and Information Technology, it goes without saying that the focus has been shifted from the System Oriented software to the User Oriented software. Naturally, for such software applications, the importance of User Experience has gained a paradigm shift. The paper highlights the significance of a seamless interaction between the user and the computer by proposing a reliable algorithm for performing basic operations by drawing gestures with a mouse. It aims to embrace simplicity and quick access using gestures and providing effortless interaction for the uniquely abled users. The core of the algorithm comes from the Hidden Markov Model, which is emblematic of a probabilistic approach for gesture recognition. DOI: 10.17762/ijritcc2321-8169.15050

Patiromer for the treatment of hyperkalemia

INTRODUCTION: Hyperkalemia is a chronic and life-threatening electrolyte disorder that affects millions of patients around the world with decreased kidney function, hypertension, and heart failure. Recently newer oral potassium-binding agents have been approved for clinical use, as an alternative to the decades long use of sodium polystyrene sulfonate. This review will focus on the patiromer and its use in reducing hyperkalemia. AREAS COVERED: Pubmed was used to search from 1960 to 2020 on free subject terms: Hyperkalemia, Potassium, Patiromer, Veltassa, Kayexalate, Sodium polystyrene sulfonate, and Sodium Zirconium cyclosilicate. The authors have reviewed the literature and summarized the most salient elements in regards to patiromer. EXPERT OPINION: Patiromer has been available on the US market since 2015 when approved by the FDA for clinical use. Clinical trials monitoring patient use for up to 1 year have shown clinically meaningful potassium reductions, sustained normokalemia, high tolerability, and without major serious adverse events. Patiromer is available to all patients experiencing hyperkalemia, no matter the disease state leading to the condition. It is likely this newer oral potassium-binding agent will help change how patients with hyperkalemia are treated in regards to sudden and chronic medical conditions

COVID-19 Extrapulmonary illness - The Impact of COVID-19 on Nephrology care

Coronavirus disease-2019 (COVID-19) has caused a pandemic that has affected millions of people worldwide. COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and is spread by close contact and by respiratory droplets. It has also impacted different aspects of caring for people with kidney disease, including those with acute kidney injury (AKI), chronic kidney disease (CKD), those requiring kidney replacement therapy (KRT), and those with a kidney transplant. All of these patients are considered high risk. The lessons learned from the COVID-19 pandemic will hopefully serve to protect patients with kidney disease in a similar situation in the future